Innate Pharma (IPHA) Stock Price, News & Analysis

Company Overview

Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune cells that can recognize and attack tumors. Its product candidates include monoclonal antibodies, immune-cell engagers and other treatments designed to stimulate or direct immune responses against cancer.

Innate Pharma’s pipeline has included lacutamab, an antibody targeting KIR3DL2 for the treatment of certain T-cell lymphomas, including cutaneous T-cell lymphoma. The company has also developed additional innate immune cell-engaging programs and has pursued research collaborations and licensing arrangements with larger pharmaceutical companies, including programs involving antibodies designed to activate natural killer cells.

Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and clinical development activities in France and the United States and works with international pharmaceutical partners. The company is listed on Euronext Paris and its American depositary shares trade on the Nasdaq Global Select Market under the symbol IPHA.

Key Stats

• Today's Range: $1.53 to $1.69
• 50-Day Range: $1.56 to $2.54
• 52-Week Range: $1.17 to $2.71
• Volume: 106,871 shs
• Average Volume: 55,349 shs
• Market Capitalization: $176.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.67
• Consensus Rating: Moderate Buy

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 201st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Innate Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Innate Pharma has a consensus price target of $6.67, representing about 321.9% upside from its current price of $1.58.

Amount of Analyst Coverage

Innate Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Innate Pharma are expected to grow in the coming year, from ($0.53) to ($0.45) per share.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 4.09.

Change versus previous month

Short interest in Innate Pharma has recently decreased by 7.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Innate Pharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Innate Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.16% of the stock of Innate Pharma is held by institutions.

Company Calendar

• Today: 10/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IPHA
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: 33-4-30-30-30-30
• Fax: N/A
• Employees: 163
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Innate Pharma: $6.67
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +321.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $10.19 million
• Price / Sales: 17.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.26) per share
• Price / Book: -6.08

Miscellaneous

• Outstanding Shares: 111,720,000
• Free Float: 76,092,000
• Market Cap: $176.52 million
• Optionable: Not Optionable
• Beta: 0.72